Back to Homepage
Search
Advanced Search
Chicago 2012

Click here for the EyeWorld Show Daily Wrap-Up

Ophthalmology Business

View Latest Issue
Resources

Ophthalmologists

Practice Managers

Patient Education

EyeSpaceMD

IOL Calculator
Clinical Study Update: Surgical Therapeutics


      Contents


1.   Aqueous Penetration and Biological Activity of Moxifloxacin 0.5% and Gatifloxacin 0.3% Ophthalmic Solutions in Cataract Surgery Patients

2.   Moxifloxacin shown to have greater potency and better penetration
      Stephen S. Lane, M.D

3.   A Double-Masked, Randomized, Single-Dose, Pharmacokinetic Study of NEVANAC® Suspension, ACULAR* LS, or XIBROM* in Human Aqueous Humor

4.   NEVANAC® suspension shows greater ocular bioavailability than other NSAIDs
      Michael B. Raizman, M.D.

5.   Human Corneal Concentrations of Moxifloxacin and Gatifloxacin in a Penetrating Keratoplasty Model

6.   VIGAMOX® solution shown to have greater human corneal concentration than ZYMAR*
      Terry Kim, M.D.

7.   A Double-Masked Study of Nepafenac 0.1% and Ketorolac 0.4% for Pain and Epithelial Healing Following PRK

8.   Epithelial healing shown to be equivalent among NSAIDs
      Daniel S. Durrie, M.D.

9.   Evaluation of the Safety of Prophylactic Intracameral VIGAMOX® Solution in Cataract Surgery Patients

10.   Intracameral VIGAMOX® solution shown to be safe after cataract surgery
      Francis Mah, M.D.

11.   Placebo-Controlled Trial of NEVANAC® Suspension and ACULAR* for Treatment of Ocular Pain and Inflammation Following Cataract Surgery

12.   NEVANAC® suspension effective for post-op cataract surgery inflammation and pain
      Edward J. Holland, M.D.






ASCRS
Copyright © 1997-2013 EyeWorld News Service
This site is optimized for 1024 X 768 Resolution


Visit EyeWorld.mobi for a PDA optimized experience